The Venture Codex Logo

The Venture Codex

Sussex Place Ventures

58-60 Fitzroy Street, London, England, W1T 5BU, United Kingdom

Overview

Sussex Place Ventures is an early-stage venture capital investor, backing entrepreneurs building enterprise software and businesses with strong patent-protectable technology. They are an independently managed venture capital management company sitting within the London Business School ecosystem and have been investing in early-stage technology companies for over a decade.

Total investments
15
Lead investments
4
Investments · 12mo
0
Active investors
4

Sector focus

  • Finance
  • Financial Services
  • Venture Capital
Visit website

Investment portfolio

  • Entia

    Participated · Series A · Jul 2023

    Entia builds remote patient monitoring tools for people undergoing cancer treatment, centered on its Liberty at-home blood-testing device. Liberty enables regular home-based blood checks to detect treatment-related conditions such as neutropenia, aiming to identify problems earlier and reduce unplanned hospitalisations. The approach is intended to move routine health assessments out of hospitals, improve patient experience, and help keep patients on treatment longer, potentially improving survival outcomes. The company plans to roll out its monitoring system across the UK and is pursuing regulatory approval in the US. Entia recently raised £16 million in a Series A to fund these efforts. Investors in the round include BGF, Parkwalk, Sussex Place Ventures, Innovate UK and other undisclosed backers. Entia is led by CEO and founder Dr. Toby Basey-Fisher. Entia has developed Entia Liberty, a virtual oncology service that uses a home blood analyser to let patients perform a suite of blood tests, initially focused on full blood counts to monitor haematological toxicity. Results are shared with healthcare professionals via Entia’s cloud network and integration tools to support personalised clinical decisions and earlier intervention. The service is at later stages of development and is pending regulatory approval; it is currently not available for sale. Entia has formed clinical and commercial partnerships, including with The Christie NHS Foundation Trust and a commercial partnership with Pfizer UK to make the service available for metastatic breast cancer patients in the UK following approval. The company was founded in 2015 and is based in London. Entia has previously raised over $13 million (including support from Innovate UK’s Biomedical Catalyst programme) and most recently secured additional funding to launch Liberty and meet international demand.

  • Cutover

    Participated · Series B · Mar 2021

    Cutover provides an enterprise work orchestration and observability platform used to plan, orchestrate and analyze complex releases, cloud migrations, incident responses and other timebound work involving humans and machines. The platform offers audit trails, visibility and control to support operational resilience and faster, more reliable change at scale. Cutover says its revenues doubled and it almost tripled its workforce in 2020 as demand for distributed and remote collaboration rose. Customers include leading firms across financial services (including three of the top five U.S. banks), technology, retail and insurance, and partners include Accenture, Barclays and Deloitte. The company is an Advanced Technology Partner and ISV to AWS and works with a broad partner ecosystem. Cutover plans to expand into new verticals, double engineering and product investment, enhance integrations and open API connectivity, and increase sales, customer success and solution delivery capacity. Cutover provides a cloud-enabled work orchestration and observability platform that brings dynamic flows of work out of the enterprise 'dark matter' to give teams visibility and control. The platform replaces static spreadsheets and weekend calls, enabling teams to plan, orchestrate and analyze human and automated activities for technology releases, resilience testing, operational readiness and incident recovery. Cutover is used by many leading global banks and wider financial services firms and targets use cases such as hybrid cloud migration, data center migration, continuous transformation and operational resilience. The company says the new funding will increase its development capability fourfold and support rapid expansion into new verticals. Cutover plans to build its product development and client teams and prototype new areas of the platform in partnership with clients. The company emphasizes enabling humans and machines to collaborate more effectively and reducing the risk of failure across complex enterprise changes.

  • Endomag

    Participated · Series D · Nov 2020

    Endomag develops magnetic sensing technologies for breast cancer localisation and staging, centered on its Sentimag® platform. Its core products include the Sentimag® localisation system, the Magseed® magnetic seed for tumour localisation, and Magtrace® liquid tracer for lymph node mapping. The company says its technologies have helped over 130,000 women worldwide and have enabled procedures such as targeted axillary dissection (TAD) and delayed sentinel lymph node biopsy (dSLNB) that can reduce surgical invasiveness. Endomag plans to use new capital to expand access to advanced techniques (TAD and dSLNB), scale its product offering, market reach and workforce. It continues to invest in research and development and expects to launch a next‑generation Sentimag® platform and new Magseed® products in 2021. Headquartered in Cambridge, UK, with an office in Austin, Texas, the company currently operates in 43 countries and aims to expand further. Endomagnetics develops magnetic-sensing tools and the Sentimag® platform (including the Magseed® magnetic marker) for minimally invasive surgical guidance to localize breast cancers and sentinel nodes. Its technology aims to replace wire placement with a patient-centred clip/marker workflow that improves accuracy, safety, and efficiency. The company reports its products have been used in over 35,000 procedures across 300 hospitals in more than 30 countries. With recent regulatory progress (a 510(k) FDA clearance to extend Magseed use) Endomag is positioned to expand in the U.S. and other markets. The business plans to rapidly expand commercial activity and pursue planned product development to treat more cancer patients worldwide. Financially, the company has raised additional capital to support scaling its commercial operations and R&D.

  • Chaser

    Participated · Equity · Nov 2019

    Chaser provides a cloud credit control software platform that automates chasing customers to pay invoices for accountants and bookkeepers. Founded by David Tuck, the platform sends automatic and intelligent email chasers to help get invoices paid on time. To date the company says users have chased over $2.2 billion worth of invoices through the software. It also operates ChaseAcademy, a virtual credit control service incubator launched in August 2019 offering a 12-week program that equips accountants and bookkeepers to offer outsourced credit control to SMEs. The company plans to use new funding to expand its product development team and continue rolling out new features through 2020. Chaser's product focus is enabling accountants and bookkeepers to provide professional-level credit control as a service, allowing SMEs to outsource their credit control processes.

  • Gluru

    Participated · Seed · Nov 2016

    Gluru is a UK-based startup building an AI-powered smart to-do list that automatically converts communications into actionable tasks. Its first product is available on web and Android, with an iOS version in beta, and currently syncs with Gmail and Google Calendar to identify daily tasks and suggest actions. The company says it uses a multi-patented combination of natural language processing, deep learning, and ontology to parse 'conversational data sources.' Gluru learns from user interactions to automate repetitive tasks and flag items requiring attention, with a vision to predict complementary actions and answers. Planned integrations include Outlook, Slack, Alexa, Google Drive, Dropbox, and Salesforce, and the product is intended to live inside those ecosystems to power productivity. Financially, Gluru raised a $2 million seed round from Sussex Place Ventures, SaatchInvest, Gecad and Playfair Capital, bringing total funding to $3.5 million. Gluru applies advanced machine-learning and natural-language-processing to multiple file-based data sources to learn how a person lives and works. Its algorithms organize files and predict when a user will need specific content, then surface relevant information automatically in context such as calls, emails and appointments. Led by founder and CEO Tim Porter, the company plans to release its first app, Gluru Assistant, in Q1 2015. The company intends to use new funding to expand the team, accelerate product development and cross-platform offerings, and bolster infrastructure across sales, marketing and communications. The product strategy centers on triggering intelligent, instant content delivery to users' devices based on contextual cues. Gluru is headquartered in London, UK.

Team

  • John Bates

    Founder & Board Member

  • Richard Gourlay

    Managing Director

    LinkedIn
  • Barnaby Terry

    Managing Partner

    LinkedIn
  • John Brimacombe

    Operating Partner

    LinkedIn